Radioligand Therapy in Pediatric Cancer: How Targeted Radiation Is Changing Treatment for Children

What Is Radioligand Therapy and How Does It Work in Children?

Radioligand therapy (RLT) represents a growing area of precision oncology that pairs a targeting molecule — one that seeks out specific proteins on cancer cells — with a radioactive isotope capable of destroying those cells from within. Unlike conventional external beam radiation, which irradiates broader areas of tissue, RLT delivers its payload with molecular specificity, potentially reducing the collateral damage that is especially concerning in developing pediatric bodies.

The approach is part of a broader discipline known as theranostics, which integrates diagnostic imaging and therapeutic delivery using the same or similar molecular agents. A diagnostic scan first confirms that a child's tumor expresses the target receptor; if it does, a therapeutic version of the agent is administered to treat the disease. This diagnostic-first model helps clinicians identify which patients are most likely to benefit, avoiding unnecessary treatment and its associated side effects.

Why Is Pediatric Oncology Investing in Theranostic Research Now?

The expansion of theranostic capabilities into pediatric oncology follows years of demonstrated success in adult cancers. Lutetium-177 DOTATATE (Lutathera), approved by the FDA for gastroenteropancreatic neuroendocrine tumors, and lutetium-177 PSMA-617 (Pluvicto), approved for metastatic castration-resistant prostate cancer, have validated the clinical model. Researchers are now investigating whether similar approaches can be adapted for childhood malignancies, including neuroblastoma, certain brain tumors, and sarcomas that express targetable surface markers.

Children who undergo conventional chemotherapy and radiation face long-term risks including secondary cancers, organ damage, cognitive impairment, and growth abnormalities. According to the National Cancer Institute, approximately two-thirds of childhood cancer survivors experience at least one chronic health condition related to their treatment. This burden has created urgency around developing therapies that are effective against the cancer while minimizing harm to the rest of the body — a goal that radioligand therapy is well-positioned to address.

What Are the Challenges Facing Pediatric Radioligand Therapy?

Despite the promise, significant challenges remain before radioligand therapy becomes a standard option in pediatric oncology. Clinical trials in children are inherently more complex, requiring stringent ethical oversight and careful dosimetry to account for smaller body sizes and developing organs. The number of pediatric patients with any single cancer type is relatively small, making it difficult to recruit for large-scale randomized trials that regulators typically require for approval.

Infrastructure is another barrier. Theranostic programs require cyclotrons or access to radiopharmaceutical supply chains, specialized nuclear medicine teams, and radiation safety protocols adapted for pediatric patients. Academic medical centers and children's hospitals are beginning to build dedicated theranostic research facilities, but widespread availability remains years away. The collaboration between research institutions, pharmaceutical developers, and regulatory agencies will be critical to accelerating access for the children who may benefit most.